ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02156362
Previous Study | Return to List | Next Study

Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02156362
Recruitment Status : Recruiting
First Posted : June 5, 2014
Last Update Posted : July 6, 2017
Sponsor:
Information provided by (Responsible Party):
Hospices Civils de Lyon

Brief Summary:

It is generally estimated that 5 % of patients with thyroid cancer will develop distant metastases, and most of them had an advanced stage of the disease at presentation. Thirty per cent of them are resistant to radio iodine therapy and are called "refractory". Their long term survival is estimated to be less than 10 %.

The objective of this study is to identify the factors associated with poor outcome in a cohort of patients with advanced thyroid cancer followed during 5 years. Anaplastic and medullary thyroid carcinomas were excluded.


Condition or disease Intervention/treatment Phase
Thyroid Cancer Other: follow up visit Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 650 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)
Actual Study Start Date : May 2012
Estimated Primary Completion Date : May 2023
Estimated Study Completion Date : May 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
follow up Other: follow up visit
At least 1 follow up visit per year will be done and an additional visit if needed.




Primary Outcome Measures :
  1. Rate of Thyroid cancer evolving to refractory stage [ Time Frame: 5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Man or woman ≥ 18 years.
  • Thyroid cancer differentiated from follicular origins (papillary, vesicular or poorly differentiated carcinoma).
  • TNM classification: stage pT3 (≥2 cm), or pT4 or M1 at diagnosis.
  • Patient after post operative radioiodine therapy.

Exclusion Criteria:

  • Patient who can not be followed during the protocol.
  • Patient who does not consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02156362


Contacts
Contact: Claire BOURNAUD, MD +33472356999 claire.bournaud-salinas@chu-lyon.fr
Contact: Françoise BORSON-CHAZOT, PHD,MD +33472119319 francoise.borson-chazot@chu-lyon.fr

Locations
France
Hospices Civils de Lyon-Centre de Médecine Nucléaire Groupement Hospitalier Est 59 boulevard Pinel Recruiting
Bron cedex, France, 69677
Contact: Claire BOURNAUD, MD    +33472356999    claire.bournaud-salinas@chu-lyon.fr   
Contact: Françoise BORSON-CHAZOT, PHD,MD    +33472119319    francoise.borson-chazot@chu-lyon.fr   
Principal Investigator: Claire BOURNAUD, MD         
Sponsors and Collaborators
Hospices Civils de Lyon
Investigators
Principal Investigator: Claire BOURNAUD, MD Hospices Civils de Lyon- Centre de Médecine Nucléaire Groupement hospitalier est, 59 boulevard Pinel, 69677 Bron cedex

Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT02156362     History of Changes
Other Study ID Numbers: 2011.665
First Posted: June 5, 2014    Key Record Dates
Last Update Posted: July 6, 2017
Last Verified: July 2017

Keywords provided by Hospices Civils de Lyon:
Thyroid carcinoma
predictive factors
refractory
Differentiated
follicular origin

Additional relevant MeSH terms:
Carcinoma
Thyroid Diseases
Thyroid Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms